NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Medical Devices · USD

Axogen, Inc. (AXGN) Stock Analysis

Axogen, Inc. (AXGN) is a Medical Devices stock listed on NASDAQ and quoted in US Dollar.

AXGN

$48.28

+$1.18 (+2.51%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare AXGN with… →

AXGN Key Statistics

As of Sep 4, 2026
Trading
Open
$46.73
Previous Close
$47.10
Day's Range
46.29–48.39
52-Week Range
15.27–52.91
Volume
550.10K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.16
Valuation
Market Cap
$2.60B
P/E Ratio
unprofitable
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
69.59
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
99.04
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
10.33
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.69
Financials (FY)
Revenue (FY)
$225.21M+20.21%
Net Income (FY)
−$15.70M
Profit marginThe share of revenue left as profit after all costs and taxes.
−13.36%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
53.76M
1-Year Return
+213.51%
Dividend and dates
Earnings Date
October 28, 2026
Avg Volume
1.24M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

AXGN Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+47.51%
2025+98.60%
2024+141.29%
2023−31.56%
2022+6.51%
2021−47.65%
2020+0.06%
2019−12.43%
2018−27.81%
2017+214.44%
2016 (partial year)+6.64%

As of September 4, 2026.

AXGN Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$225.21M−$15.70M−7.0%
2024$187.34M−$9.96M−5.3%
2023$159.01M−$21.72M−13.7%
2022$138.58M−$28.95M−20.9%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$225.21M$167.35M−$7.85M−$15.70M−7.0%
2024$187.34M$141.98M−$3.29M−$9.96M−5.3%
2023$159.01M$121.87M−$21.46M−$21.72M−13.7%
2022$138.58M$108.81M−$29.71M−$28.95M−20.9%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

AXGN Valuation vs Medical Devices Median

Median of 151 stocks
MetricAXGNMedical Devices medianvs median
P/S ratio10.332.983.5x the median
Profit margin−13.36%−1.69%11.7 pts below

Medians across 151 Medical Devices stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 11 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Axogen, Inc. (AXGN) is capitalised at $2.60B on the latest close. It is classified in the Medical Devices industry, within the Healthcare sector. The company reports 622 employees.

The 52-week range on file runs from $15.27 to $52.91. AXGN last closed at $48.28 on September 4, 2026. That is +$1.18 (+2.51%) against the previous close. The latest close sits 216.18% above that 52-week low.

Financial Health

In fiscal 2025, Axogen, Inc. reported revenue of $225.21M. That is +20.21% against the prior fiscal year, when revenue was $187.34M. The same year closed with a net loss of $15.70M. Profit margin runs at −13.36%. That is 11.7 percentage points below the Medical Devices median of −1.69%. Earnings per share on a trailing basis come to −0.69.

Across the 4 fiscal years on file, revenue moves from $138.58M in 2022 to $225.21M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. On forward earnings the ratio is 69.59. The PEG ratio, which sets the P/E against expected earnings growth, reads 99.04. Measured against sales, the shares trade at 10.33 times revenue. On price-to-sales that is 3.5 times the Medical Devices median of 2.98. 151 Medical Devices companies report these metrics, and the medians quoted come from that group.

The reported beta is 1.16. Daily returns over the trailing 10 years annualize to a volatility of 61.95%. Over the trailing twelve months the price has returned +213.51%. Measured over 10 years, that is +18.44% a year compounded.

Growth & Income

The record shows no dividend for AXGN.

The strongest complete calendar year on file is 2017 at +214.44%; the weakest is 2021 at −47.65%. Of the 9 complete calendar years on file, 5 finished higher. 2026 is still running; the price is +47.51% year to date.

Peer Comparison

Axogen, Inc. (AXGN) operates in the Medical Devices industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Axogen, Inc. AXGN $2.60B —
Abbott Laboratories ABT $187.45B 35.1
Medtronic plc. MDT $120.46B 22.9
Stryker Corporation SYK $116.27B 31.9

The Medical Devices industry average P/E ratio is 26.8x. Axogen, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Medical Devices Stocks

ABT

Abbott Laboratories

$187.45B

 MDT

Medtronic plc.

$120.46B

 SYK

Stryker Corporation

$116.27B

 BSX

Boston Scientific Corporation

$69.27B

 EW

Edwards Lifesciences Corporation

$51.82B

 DXCM

DexCom, Inc.

$33.17B
View all Medical Devices stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Axogen, Inc.

Axogen, Inc., together with its subsidiaries, engages in the development and commercialization of the technologies used for peripheral nerve regeneration and repair worldwide. The company offers Avance Nerve Graft, a processed nerve allograft intended for the surgical repair of peripheral nerve discontinuities; Axoguard Nerve Connector, a coaptation aid used to align and connect severed peripheral nerve ends in a tensionless repair; and Axoguard Nerve Protector, a product used to protect and wrap damaged peripheral nerves and reinforce reconstructed nerve gaps. It also provides Axoguard HA+ Nerve Protector, a surgical implant for non-constricting protection of the peripheral nerves; Axoguard Nerve Cap, a porcine submucosa ECM product; Avive+ Soft Tissue Matrix, a multi-layer amniotic membrane allograft; and Avance Method, a technique to process Avance Nerve Graft from donated human peripheral nerve tissue. In addition, the company offers peripheral nerve tissue recovery and acquisition, and testing, as well as donor medical review and release, debridement and other processing steps, packaging, and sterilization. It provides its products to hospitals, surgery centers and military hospitals, calling on surgeons, including plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and certain oral and maxillofacial surgeons through independent in-country distributors. The company is headquartered in Alachua, Florida.

Visit website →